Seagen - SGEN Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGEN shares.
View SGEN analyst ratings or view top-rated stocks.

12 brokerages have issued 1-year target prices for Seagen's shares. Their SGEN share price forecasts range from $145.00 to $220.00. On average, they expect the company's share price to reach $180.36 in the next year. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen's stock was trading at $154.60 at the start of the year. Since then, SGEN stock has decreased by 12.2% and is now trading at $135.70.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our SGEN earnings forecast.

Seagen Inc. (NASDAQ:SGEN) posted its earnings results on Thursday, July, 28th. The biotechnology company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.09. The biotechnology company had revenue of $497.50 million for the quarter, compared to analysts' expectations of $437.77 million. Seagen had a negative trailing twelve-month return on equity of 24.33% and a negative net margin of 41.61%. The firm's quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) earnings per share.

Seagen updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.71 billion-$1.79 billion, compared to the consensus revenue estimate of $1.78 billion.

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $135.70.

Seagen (NASDAQ:SGEN) has a market capitalization of $25.03 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis.

The company employs 2,675 workers across the globe.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.